Clinical Trial Update: An Investigational Immuno-therapy Study of BMS-986205 Given in Combination With Nivolumab and in Combination With Both Nivolumab and Ipilimumab in Cancers That Are Advanced or Have Spread [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial investigating BMS-986205 with nivolumab alone and with nivolumab plus ipilimumab in advanced cancers, including melanoma and non-small cell lung…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cancer
• Melanoma
• Non-small Cell Lung Cancer

Drugs mentioned

• BMS-986205 (BMS-986205)
• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Advanced Cancer, Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-08-28